VECT Stock - VectivBio Holding AG
Unlock GoAI Insights for VECT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|
| Revenue | $27.34M | N/A | N/A | N/A |
| Gross Profit | $27.34M | N/A | N/A | N/A |
| Gross Margin | 100.0% | N/A | N/A | N/A |
| Operating Income | $-80,524,000 | $-86,716,000 | $-57,261,000 | $-24,315,000 |
| Net Income | $-93,735,000 | $-87,009,000 | $-60,497,000 | $-23,531,000 |
| Net Margin | -342.8% | N/A | N/A | N/A |
| EPS | $-2.12 | $-3.23 | $-2.40 | $-1.01 |
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 13th 2022 | Jefferies | Initiation | Buy | $18 |
| July 1st 2022 | Piper Sandler | Initiation | Overweight | $23 |
Earnings History & Surprises
VECTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2023 | Apr 19, 2023 | $-0.52 | — | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.65 | — | — |
Q3 2022 | Jul 7, 2022 | $-0.64 | $-1.48 | -131.1% | ✗ MISS |
Q2 2022 | Apr 7, 2022 | $-0.61 | — | — | — |
Q4 2021 | Dec 31, 2021 | — | $-1.61 | — | — |
Q4 2021 | Oct 29, 2021 | $-0.57 | — | — | — |
Q2 2021 | Jun 30, 2021 | — | $-1.61 | — | — |
Q2 2021 | Apr 9, 2021 | — | — | — | — |
Q4 2020 | Dec 31, 2020 | — | $-1.30 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-1.30 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.50 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.50 | — | — |
Latest News
Frequently Asked Questions about VECT
What is VECT's current stock price?
What is the analyst price target for VECT?
What sector is VectivBio Holding AG in?
What is VECT's market cap?
Does VECT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VECT for comparison